Patel Sanjiv sold $872K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.10 ($0.87M total) on 2026-10-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size and may cause a brief dip in RLAY shares, but likely not a sustained move.
Market read
A routine insider sale with limited material impact; traders may watch for any follow‑up activity.
What to watch
Potential upcoming corporate actions or financing needs not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; investors monitor them for signals about management confidence.
Ticker impact
President and CEO Sanjiv Patel sold 48,199 shares for $872,401, reducing his stake to 471,301 shares.
likely slight pressure as the market prices in the insider sell
The sale is under $1M and represents a modest reduction in holdings; such transactions typically cause minor short-term downside.
Market effects
Minimal impact on biotech sector; insider sales are common and rarely shift sector sentiment.
None
None
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- CompanyRelay Therapeutics, Inc.
Biopharma developing protein modulation therapies.
- ExecutiveSanjiv Patel
President and CEO of Relay Therapeutics.